Fujii T - Search Results

1

Otsuki T, Yata K, Sakaguchi H, Uno M, Fujii T, Wada H, Sugihara T, Ueki A. Otsuki T, et al. Among authors: fujii t. Leuk Lymphoma. 2002 May;43(5):969-74. doi: 10.1080/10428190290021579. Leuk Lymphoma. 2002. PMID: 12148907 Review.

2

Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells.

Otsuki T, Yata K, Sakaguchi H, Kurebayashi J, Matsuo Y, Uno M, Fujii T, Eda S, Isozaki Y, Yawata Y, Yamada O, Wada H, Sugihara T, Ueki A. Otsuki T, et al. Among authors: fujii t. Br J Haematol. 2002 Mar;116(4):787-95. doi: 10.1046/j.0007-1048.2002.03336.x. Br J Haematol. 2002. PMID: 11886382 Free article.

3

Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells.

Yata K, Otsuki T, Kurebayashi J, Uno M, Fujii T, Yawata Y, Takata A, Hyodoh F, Sugihara T. Yata K, et al. Among authors: fujii t. Int J Oncol. 2003 Jan;22(1):165-73. Int J Oncol. 2003. PMID: 12469200

4

IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor.

Otsuki T, Sakaguchi H, Eto M, Fujii T, Hatayama T, Takata A, Tsujioka T, Sugihara T, Hyodoh F. Otsuki T, et al. Among authors: fujii t. Int J Oncol. 2003 Sep;23(3):763-8. Int J Oncol. 2003. PMID: 12888915

5

Expression of HER family receptors and effects of anti-HER2-antibody on human myeloma cell lines.

Otsuki T, Kurebayashi J, Ohkubo S, Uno M, Fujii T, Sakaguchi H, Hatayama T, Takata A, Tsujioka T, Sugihara T, Hyodoh F. Otsuki T, et al. Among authors: fujii t. Int J Oncol. 2003 Oct;23(4):1135-41. Int J Oncol. 2003. PMID: 12963996

6

Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells.

Otsuki T, Sakaguchi H, Hatayama T, Fujii T, Tsujioka T, Sugihara T, Takata A, Hyodoh F, Eto M. Otsuki T, et al. Among authors: fujii t. Oncol Rep. 2004 May;11(5):1053-8. Oncol Rep. 2004. PMID: 15069546

7

Participation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiation.

Uno M, Otsuki T, Yata K, Fujii T, Sakaguchi H, Akisada T, Hiratsuka J, Imajo Y, Harada T. Uno M, et al. Among authors: fujii t. Int J Oncol. 2002 Mar;20(3):617-22. Int J Oncol. 2002. PMID: 11836578

8

Effect of hypoxia on human seminoma cells.

Fujii T, Otsuki T, Moriya T, Sakaguchi H, Kurebayashi J, Yata K, Uno M, Kobayashi T, Kimura T, Jo Y, Kinugawa K, Furukawa Y, Morioka M, Ueki A, Tanaka H. Fujii T, et al. Int J Oncol. 2002 May;20(5):955-62. Int J Oncol. 2002. PMID: 11956589

9

Possible mechanism responsible for the acquisition of resistance to cis-diamminedichloroplatinum (II) by cultured human testicular seminoma cells.

Kobayashi T, Fujii T, Jo Y, Kinugawa K, Fujisawa M. Kobayashi T, et al. Among authors: fujii t. J Urol. 2004 May;171(5):1929-33. doi: 10.1097/01.ju.0000122901.70300.20. J Urol. 2004. PMID: 15076314

10

High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.

Jo Y, Hiratsuka J, Fujii T, Takenaka A, Fujisawa M. Jo Y, et al. Among authors: fujii t. Urology. 2004 Sep;64(3):556-60. doi: 10.1016/j.urology.2004.04.015. Urology. 2004. PMID: 15351592 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,542 results

Search Page

Filters